Sua seleção (0)
Detalhe da pesquisa
1.
Targeting chronic myeloid leukemia stem cells with the hypoxia-inducible factor inhibitor acriflavine.
Blood;
130(5): 655-665, 2017 08 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28576876
2.
Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice.
Haematologica;
104(8): 1589-1596, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-30819917
3.
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart.
Hematol Oncol;
37(3): 296-302, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-30892724
4.
Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline.
Ann Hematol;
98(10): 2329-2338, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-31392461
5.
Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice.
Ann Hematol;
97(9): 1577-1580, 2018 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-29675611
6.
Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series.
Ann Hematol;
97(1): 95-100, 2018 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-28971265
7.
Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia.
Am J Hematol;
91(6): 617-22, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-26971721
8.
Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study.
Am J Hematol;
90(10): 910-4, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26178642
9.
Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement.
Cancer;
120(7): 1002-9, 2014 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24382642
10.
Chronic myeloid leukaemia with extreme thrombocytosis at presentation: incidence, clinical findings and outcome.
Br J Haematol;
181(2): 267-270, 2018 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-28169426
11.
Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors.
Haematologica;
98(3): 399-403, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-22801965
12.
Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia.
Hematol Oncol;
31(2): 103-9, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-22815278
13.
Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia.
Ann Hematol;
92(2): 179-83, 2013 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-23053188
14.
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis.
Am J Hematol;
93(7): E159-E161, 2018 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-29633312
15.
Stiff skin syndrome and myeloma successfully treated with autologous haematopoietic stem cell transplantation (HSCT).
Clin Exp Rheumatol;
31(2 Suppl 76): 181-3, 2013 Mar-Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-23910622
16.
Distinct signal transduction abnormalities and erythropoietin response in bone marrow hematopoietic cell subpopulations of myelodysplastic syndrome patients.
Clin Cancer Res;
18(11): 3079-89, 2012 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22496271
17.
Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy.
Cancer;
118(21): 5265-9, 2012 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22517301
18.
Mutated ASXL1 and number of somatic mutations as possible indicators of progression to chronic myelomonocytic leukemia of myelodysplastic syndromes with single or multilineage dysplasia.
Haematologica;
102(9): e332-e335, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28522578
19.
Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.
Blood;
114(10): 2168-71, 2009 Sep 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-19589924
20.
Efficacy and safety of second-line ponatinib after failure of a single previous tyrosine kinase inhibitor for chronic myeloid leukemia patients in chronic phase.
Haematologica;
101(6): e267-8, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-27252515